Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Nakhlis F, et al. Among authors: tolaney sm. Breast Cancer Res Treat. 2024 Apr;204(2):289-297. doi: 10.1007/s10549-023-07195-5. Epub 2023 Dec 28. Breast Cancer Res Treat. 2024. PMID: 38155272
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. Among authors: tolaney sm. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I. Tolaney S, et al. Breast Cancer Res Treat. 2015 Jan;149(1):151-61. doi: 10.1007/s10549-014-3248-4. Epub 2014 Dec 24. Breast Cancer Res Treat. 2015. PMID: 25537644 Clinical Trial.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. N Engl J Med. 2015. PMID: 25564897 Free PMC article. Clinical Trial.
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Ruddy KJ, et al. Among authors: tolaney sm. Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16. Breast Cancer Res Treat. 2015. PMID: 25981899 Free PMC article.
308 results